Table 6.

Self-Reported and Validated Abstinence Among Recipients of Pharmacotherapy Management (PM), Moderate-Intensity Disease Management (MDM) and High-Intensity Disease Management

Table 6a 7-Day Point Prevalence Abstinence Self-Report and Validated*
Outcomes	PM	MDM	HDM
	7-Day Point Prevalence, N (%)
Month 6	26/247 (10.5)	36/245 (14.7)	41/249 (16.5)
Month 12	38/247 (15.4)	49/244 (20.1)	60/248 (24.2)
Month 18	35/247 (14.2)	40/240 (16.7)	59/245 (24.1)
Month 24	56/244 (23.0)	56/238 (23.5)	68/244 (27.9)
	Validated 7-Day Point Prevalence, N (%)
Month 12†	13/247 (5.3)	24/244 (9.8)	28/248 (11.3)
Month 24‡	33/244 (13.5)	35/238 (14.7)	36/244 (14.8)

Table 6b Statistical Comparisons
	HDM vs. MDM		(HDM & MDM) vs. PM
Analysis	Odds Ratio (95% CI)	P value	Odds Ratio (95% CI)	P value
Point Prevalence Estimates
24 month, (no imputation; n = 708)§	1.31 (0.85–2.02)	0.22	1.19 (0.82–1.73)	0.35
24 month, (missing=smoker; n = 741)§	1.33 (0.88–2.02)	0.18	1.12 (0.78–1.61)	0.54
24 month, (missing=quit; n = 741)§	1.23 (0.84–1.66)	0.30	1.42 (1.01–1.99)	0.04
12 month validated (n = 643)	1.24 (0.69–2.22)	0.47	2.33 (1.24–4.38)	0.01
24 month validated (n = 620)	1.00 (0.60–1.68)	0.99	1.19 (0.76–1.87)	0.44
Overall (0 to 24 months; no imputation; n = 708)§	1.43 (1.00–2.03)	0.05	1.47 (1.08–2.00)	0.02

^*All missing values were classified as smoking

^†Validated by salivary cotinine (< 15 ng/ml).

^‡Validated by salivary cotinine (< 15 ng/ml) or significant other.

^§GLMM for self-reported abstinence did not provide evidence for a treatment-by-time interaction (df=6, p=0.31).

Saliva samples were not provided by 33.3%, 34.7%, and 31.6% of the self-reported quitters at 12 months and by 39.7%, 33.9%, and 30.3% at 24 months in the HDM, MDM and PM groups, respectively.